Company Overview and News

 
EPA announces cleanup plan for troubled Missouri landfill

2018-09-27 nzherald.co.nz
ST. LOUIS (AP) — Some of the illegally dumped nuclear waste buried near a long-smoldering underground fire at a Missouri landfill will be dug up and the rest will be capped under a federal plan announced Thursday.
RSG EXCU EXC

15
GE's stock sinks again toward 9-year low, 3-months after Dow departure

2018-09-25 marketwatch
Shares of General Electric Co. GE, -3.96% sank 4.1% in afternoon trade Tuesday, putting them on track to close at the lowest level since July 10, 2009. The industrial conglomerate's stock has now plunged 12% in four sessions, since issues with one of its gas turbines forced Exelon Corp. EXC, -1.57% to shut down a plant, and prompt J.P. Morgan analyst Stephen Tusa to cut his price target to a Street low of $10.
GEC GE EXCU GNE EXC

15
UPDATE 2-France's EDF halts GE turbine at Bouchain, GE shares drop

2018-09-25 reuters
NEW YORK/PARIS (Reuters) - French power utility Electricite de France SA said on Tuesday it has shut down a General Electric Co turbine at its Bouchain power plant for one month due to a turbine blade issue that has shut down similar plants in the United States.
GEC GE EXCU GNE EXC

15
UPDATE 1-France's EDF halts GE turbine at Bouchain, following U.S. shutdowns

2018-09-25 reuters
NEW YORK/PARIS (Reuters) - French power utility Electricite de France SA said on Tuesday it has shut down a General Electric Co turbine at its Bouchain power plant for one month due to a turbine blade issue that has shut down similar plants in the United States.
GEC GE EXCU GNE EXC

15
France's EDF halts GE turbine at Bouchain, following U.S. shutdowns

2018-09-25 reuters
NEW YORK/PARIS, Sept 25 (Reuters) - French power utility Electricite de France SA said on Tuesday it has shut down a General Electric Co turbine at its Bouchain power plant for one month due to a turbine blade issue that has shut down similar plants in the United States.
GEC GE EXCU GNE EXC

15
GE's stock tumbles toward first sub-$12 close in over 9 years

2018-09-24 marketwatch
Shares of General Electric Co. GE, -3.84% dropped 3.7% in midday trade, putting them on track to close below the $12 mark for the first time in over nine years, as the selloff in the wake of an "issue" with a gas turbine forced a shutdown of an Exelon Corp. EXC, -0.89% facility continued for a third session. Volume ballooned to 78.5 million shares, already more than the full-day average of 52.2 million shares, and enough to make the stock the most actively traded on the NYSE.
GEC GE EXCU GNE EXC

18
Turbine Troubles Add To GE's Woes

2018-09-24 seekingalpha - 1
GE reported four of its gas turbines had to be shut down due to a problem with turbine blades.
BHI GEC GE EXCU GNE EXC

15
General Electric says blade problem affects more gas turbines

2018-09-21 channelnewsasia
General Electric Co said on Friday that turbine blade oxidation which forced Exelon Corp to idle four electric power units in Texas also affects another model, widening the impact of the latest problem to hit GE's ailing power unit.
GEC GE EXCU GNE EXC

15
UPDATE 1-General Electric says blade problem affects more gas turbines

2018-09-21 reuters
(Reuters) - General Electric Co said on Friday that turbine blade oxidation which has idled four electric power units in Texas also affects another model, widening the potential impact.
GEC GE EXCU GNE EXC

15
GE discovers flaw in latest power-plant turbines

2018-09-21 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
GEC GE EXCU GNE EXC

18
Let's Talk About General Electric's Downgrade

2018-09-21 seekingalpha - 1
Investor pessimism continues to be the name of the game for General Electric after JPMorgan Chase downgraded shares further.
GEC GE UBS EXCU GNE EXC ULSGF

27
PRESS DIGEST- Wall Street Journal - Sept 21

2018-09-21 reuters
Sept 21 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
FOX GEC GE CCV CMCSA TWX EXCU CCZ TWC ADBE CCV.CL GNE EXC FOXA CMCSK

15
Four General Electric power turbines shut down in U.S. due to blade issue

2018-09-20 reuters
(Reuters) - General Electric Co (GE.N) said on Thursday that four of its new flagship power turbines in the United States have been shut down due to an “oxidation issue” and warned it expects the problem to affect more of the 51 units it has shipped, sending shares lower.
GEC GE EXCU GNE EXC

16
GE says four of its flagship power turbines are shut down in US

2018-09-20 channelnewsasia - 1
General Electric Co has identified an "oxidation issue" that affects the lifespan of its new, larger H-class gas turbines, GE Power Chief Executive Russell Stokes said in a blog post on the company's LinkedIn page.
GEC GE EXCU GNE EXC

18
The Ratings Game: The most bearish GE analyst gets even more bearish

2018-09-20 marketwatch
J.P. Morgan’s Stephen Tusa cut his stock price target by 9% to $10, which is the lowest of the 19 analysts surveyed by FactSet
GEC GE EXCU WBA GNE EXC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EXCU / Exelon Corp., 6.50% Equity Units on message board site Silicon Investor.

E*Trade: abuses u0026 excuses E*Trade: abuses u0026 excuses E*Trade: abuses u0026 excuses Bullshit Excuses Bullshit Excuses Bullshit Excuses
CUSIP: 30161N127